Prolia (Denosumab) Rebound Effects When Stopping: What Patients and Clinicians Need to Know

Why stopping Prolia needs a plan

Denosumab is a fully human monoclonal antibody that binds RANKL and prevents it from activating RANK on osteoclasts, which reduces osteoclast formation and activity and lowers bone resorption [1]. Prolia is the 60 mg every-6-months product for osteoporosis; Xgeva is a separate product at 120 mg every 4 weeks for cancer-related bone disease, and the two are not interchangeable [1][4].

Denosumab's effect is reversible. The Prolia label states that bone turnover rises above pretreatment levels about 9 months after the last dose and returns to pretreatment values about 24 months after it, and that bone mineral density returns to pretreatment values within about 18 months [1]. The label's clinical studies section gives a shorter figure, with BMD back at approximately baseline within 12 months [1]. The discontinuation analysis of the FREEDOM trial describes the same sequence: turnover markers rose 3 months after a scheduled dose was omitted, went above baseline by 6 months, and BMD fell back to baseline by 12 months [2].

A 2026 narrative review of sequential osteoporosis treatment states that denosumab discontinuation demands structured bisphosphonate exit therapy to avoid rebound bone loss and multiple vertebral fractures [5].

How often do vertebral fractures happen after stopping?

The Prolia label warns that fracture risk increases after discontinuation, including multiple vertebral fractures; that new vertebral fractures occurred as early as 7 months after the last dose, on average 19 months after; and that a prior vertebral fracture predicts multiple vertebral fractures [1]. In the phase 3 trial, 6% of women who stopped and stayed in the study had a new vertebral fracture and 3% had multiple new vertebral fractures, with mean onset 17 months after the last dose (range 7 to 43 months) [1].

A post hoc analysis of FREEDOM and its extension followed 1,001 participants who had received at least 2 doses and stayed in the study at least 7 months after the last one. The vertebral fracture rate rose from 1.2 per 100 participant-years during treatment to 7.1 after stopping, close to the 8.5 seen in people who stopped placebo [2]. Among participants who had at least one off-treatment vertebral fracture, 60.7% of those who stopped denosumab had more than one, compared with 38.7% of those who stopped placebo (p=0.049); across all stoppers, 3.4% versus 2.2% had multiple vertebral fractures [2]. Those analyses were post hoc, not randomized comparisons [2].

A second post hoc analysis looked at 327 women who stopped placebo, 262 who stopped denosumab after 3 years or less and 213 who stopped after more than 3 years. Annualized multiple vertebral fracture rates per 100 patient-years were 3.6, 2.9 and 7.5 respectively, and longer duration was associated with multiple fractures (odds ratio 3.0) [6]. The authors describe this analysis as exploratory [6].

Who is at higher risk?

In the post hoc FREEDOM analysis, the odds of multiple vertebral fractures after stopping were 3.9 times higher (95% CI 2.1 to 7.2) in people who had sustained a vertebral fracture before or during treatment [2]. The label makes the same point, noting that prior vertebral fracture predicts multiple vertebral fractures [1]. The 2022 post hoc analysis adds treatment duration as a second signal, and its authors suggest that women stopping after more than 3 years may need closer bone-protective follow-up such as zoledronic acid [6].

What the label says to do at discontinuation

The Prolia label states that patients should be transitioned to another antiresorptive agent if Prolia is discontinued [1]. It also directs that all patients take calcium 1,000 mg daily and at least 400 IU vitamin D daily [1]. The FDA drug safety communication that added the kidney boxed warning notes that fracture risk, including in the spine, increases after stopping, skipping or delaying Prolia, and that other measures to monitor for and minimise rebound fracture risk may be advised at discontinuation [7]. The Xgeva label separately directs prescribers to evaluate a patient's risk of vertebral fractures when Xgeva is stopped [4].

Does a bisphosphonate after stopping prevent the bone loss?

Bone density still declined in a study of women who started alendronate after stopping denosumab. Without an untreated comparison group, the study cannot show how much bone loss alendronate prevented [3].

In that 2026 prospective observational study, 80 postmenopausal women who had received 2 to 22 denosumab injections (mean 9.8) started oral alendronate 70 mg weekly 6 months after their last injection, for 6 months (39 women) or 12 months (41 women). At month 12, lumbar spine BMD had fallen 5.9% across the whole group (p < 0.001), and the difference between the 6-month and 12-month arms was not statistically significant (6.8% versus 5.0%, p=0.50). Femoral neck BMD fell 3.5% [3]. Bone turnover markers rose significantly, and two of them were higher at month 12 in the 6-month group [3]. One participant (1.25%) had multiple vertebral fractures [3]. The study's main endpoint was BMD, not fractures, so it does not show how much any bridging schedule reduces fracture risk [3].

The label names no specific bridging drug, only another antiresorptive agent [1].

Advanced kidney disease: a separate boxed warning

The Prolia label carries a boxed warning for severe hypocalcemia in patients with advanced kidney disease (eGFR < 30 mL/min/1.73 m2), including dialysis-dependent patients, with hospitalisation, life-threatening events and fatal cases reported; it calls for evaluation of chronic kidney disease-mineral bone disorder before treatment and supervision by a provider experienced in its management [1]. In female dialysis-dependent Medicare patients, the 12-week cumulative incidence of severe hypocalcemia was 41.1% with denosumab versus 2.0% with oral bisphosphonates [7]. Most cases begin 2 to 10 weeks after each injection, with the greatest risk in weeks 2 to 5 [7]. For patients with advanced kidney disease, the label calls for serum calcium to be monitored weekly for the first month after Prolia administration and monthly thereafter [1].

FAQ